Free Trial
→ Every Starlink dish pays this stock (From Behind the Markets) (Ad)tc pixel Free LKFT Stock Alerts

Lakefront Biotherapeutics American Depositary Shares (LKFT) Competitors

Lakefront Biotherapeutics American Depositary Shares logo
$33.93 +0.59 (+1.77%)
As of 04:00 PM Eastern
Compare

LKFT vs. PTGX, CYTK, ABVX, ALKS, and RYTM

Should you buy Lakefront Biotherapeutics American Depositary Shares stock or one of its competitors? Lakefront Biotherapeutics American Depositary Shares's main competitors and comparable companies include Protagonist Therapeutics (PTGX), Cytokinetics (CYTK), Abivax (ABVX), Alkermes (ALKS), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lakefront Biotherapeutics American Depositary Shares compare to Protagonist Therapeutics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Protagonist Therapeutics (NASDAQ:PTGX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, dividends, earnings, valuation, profitability, risk and institutional ownership.

In the previous week, Protagonist Therapeutics had 17 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 24 mentions for Protagonist Therapeutics and 7 mentions for Lakefront Biotherapeutics American Depositary Shares. Protagonist Therapeutics' average media sentiment score of 1.03 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.64 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Protagonist Therapeutics
7 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.21, suggesting that its stock price is 21% more volatile than the broader market.

Protagonist Therapeutics has a net margin of 62.04% compared to Lakefront Biotherapeutics American Depositary Shares' net margin of 0.00%. Protagonist Therapeutics' return on equity of 42.83% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company Net Margins Return on Equity Return on Assets
Lakefront Biotherapeutics American Depositary SharesN/A N/A N/A
Protagonist Therapeutics 62.04%42.83%40.29%

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $35.50, suggesting a potential upside of 4.63%. Protagonist Therapeutics has a consensus price target of $166.67, suggesting a potential upside of 24.03%. Given Protagonist Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Protagonist Therapeutics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakefront Biotherapeutics American Depositary Shares
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38
Protagonist Therapeutics
0 Sell rating(s)
0 Hold rating(s)
16 Buy rating(s)
1 Strong Buy rating(s)
3.06

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Protagonist Therapeutics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares$1.26B1.78$363.05M-$1.41N/A
Protagonist Therapeutics$46.02M190.59-$130.15M$4.7228.47

Summary

Protagonist Therapeutics beats Lakefront Biotherapeutics American Depositary Shares on 15 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Cytokinetics?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Cytokinetics' net margin of -686.63%.

Company Net Margins Return on Equity Return on Assets
Lakefront Biotherapeutics American Depositary SharesN/A N/A N/A
Cytokinetics -686.63%N/A -48.26%

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $35.50, indicating a potential upside of 4.63%. Cytokinetics has a consensus price target of $106.67, indicating a potential upside of 89.93%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakefront Biotherapeutics American Depositary Shares
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Cytokinetics. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares$1.26B1.78$363.05M-$1.41N/A
Cytokinetics$88.04M88.86-$784.96M-$6.04N/A

In the previous week, Cytokinetics had 18 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 25 mentions for Cytokinetics and 7 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.64 beat Cytokinetics' score of 0.45 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
6 Very Positive mention(s)
2 Positive mention(s)
10 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Lakefront Biotherapeutics American Depositary Shares beats Cytokinetics on 8 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Abivax?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Abivax. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares$1.26B1.78$363.05M-$1.41N/A
AbivaxN/AN/A-$380.27M-$6.06N/A

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
Lakefront Biotherapeutics American Depositary SharesN/A N/A N/A
Abivax N/A -91.69%-71.96%

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market. Comparatively, Abivax has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market.

In the previous week, Lakefront Biotherapeutics American Depositary Shares had 1 more articles in the media than Abivax. MarketBeat recorded 7 mentions for Lakefront Biotherapeutics American Depositary Shares and 6 mentions for Abivax. Abivax's average media sentiment score of 1.29 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.64 indicating that Abivax is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Abivax
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lakefront Biotherapeutics American Depositary Shares presently has a consensus target price of $35.50, suggesting a potential upside of 4.63%. Abivax has a consensus target price of $155.00, suggesting a potential upside of 71.84%. Given Abivax's stronger consensus rating and higher possible upside, analysts clearly believe Abivax is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lakefront Biotherapeutics American Depositary Shares
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

Summary

Abivax beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 15 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

In the previous week, Alkermes had 7 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 14 mentions for Alkermes and 7 mentions for Lakefront Biotherapeutics American Depositary Shares. Alkermes' average media sentiment score of 0.86 beat Lakefront Biotherapeutics American Depositary Shares' score of 0.64 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lakefront Biotherapeutics American Depositary Shares
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lakefront Biotherapeutics American Depositary Shares has lower revenue, but higher earnings than Alkermes. Alkermes is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.48B5.35$241.66M-$0.02N/A
Lakefront Biotherapeutics American Depositary Shares$1.26B1.78$363.05M-$1.41N/A

Alkermes presently has a consensus price target of $55.06, suggesting a potential upside of 17.20%. Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $35.50, suggesting a potential upside of 4.63%. Given Alkermes' stronger consensus rating and higher possible upside, analysts plainly believe Alkermes is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
5 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.67
Lakefront Biotherapeutics American Depositary Shares
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38

95.2% of Alkermes shares are held by institutional investors. Comparatively, 32.5% of Lakefront Biotherapeutics American Depositary Shares shares are held by institutional investors. 4.6% of Alkermes shares are held by company insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Alkermes' net margin of -0.02%. Alkermes' return on equity of 0.40% beat Lakefront Biotherapeutics American Depositary Shares' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes-0.02% 0.40% 0.19%
Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Alkermes has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market.

Summary

Alkermes beats Lakefront Biotherapeutics American Depositary Shares on 15 of the 17 factors compared between the two stocks.

How does Lakefront Biotherapeutics American Depositary Shares compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and risk.

In the previous week, Rhythm Pharmaceuticals had 3 more articles in the media than Lakefront Biotherapeutics American Depositary Shares. MarketBeat recorded 10 mentions for Rhythm Pharmaceuticals and 7 mentions for Lakefront Biotherapeutics American Depositary Shares. Lakefront Biotherapeutics American Depositary Shares' average media sentiment score of 0.64 beat Rhythm Pharmaceuticals' score of 0.54 indicating that Lakefront Biotherapeutics American Depositary Shares is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rhythm Pharmaceuticals
2 Very Positive mention(s)
4 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Lakefront Biotherapeutics American Depositary Shares
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rhythm Pharmaceuticals has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, Lakefront Biotherapeutics American Depositary Shares has a beta of 0.22, meaning that its share price is 78% less volatile than the broader market.

Rhythm Pharmaceuticals presently has a consensus target price of $142.00, indicating a potential upside of 29.26%. Lakefront Biotherapeutics American Depositary Shares has a consensus target price of $35.50, indicating a potential upside of 4.63%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77
Lakefront Biotherapeutics American Depositary Shares
0 Sell rating(s)
5 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.38

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Lakefront Biotherapeutics American Depositary Shares, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rhythm Pharmaceuticals$189.76M40.14-$196.54M-$2.90N/A
Lakefront Biotherapeutics American Depositary Shares$1.26B1.78$363.05M-$1.41N/A

Lakefront Biotherapeutics American Depositary Shares has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -69.03%. Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Rhythm Pharmaceuticals-69.03% -171.16% -43.00%
Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A

Summary

Lakefront Biotherapeutics American Depositary Shares beats Rhythm Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Lakefront Biotherapeutics American Depositary Shares News Delivered to You Automatically

Sign up to receive the latest news and ratings for LKFT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LKFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LKFT vs. The Competition

Export
MetricLakefront Biotherapeutics American Depositary SharesBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.20B$4.18B$7.90B$12.24B
Dividend YieldN/A3.62%2.46%4.51%
P/E Ratio-24.0634.0334.5828.16
Price / Sales1.7817.028.905.98
Price / Cash45.9226.8922.2322.80
Price / Book0.714.164.503.83
Net Income$363.05M-$22.78M$3.51B$390.69M
7 Day Performance1.10%0.86%0.42%1.60%
1 Month Performance14.74%-7.80%-5.01%-6.85%
1 Year Performance5.01%-3.35%-0.84%-7.22%

Lakefront Biotherapeutics American Depositary Shares Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LKFT
Lakefront Biotherapeutics American Depositary Shares
2.0952 of 5 stars		$33.93
+1.8%		$35.50
+4.6%		+1.5%$2.20B$1.26BN/A1,310
PTGX
Protagonist Therapeutics
3.2848 of 5 stars		$133.96
-1.7%		$166.67
+24.4%		+57.6%$8.67B$551.69M28.38141
CYTK
Cytokinetics
3.1061 of 5 stars		$58.18
+3.6%		$106.67
+83.3%		-12.0%$8.11B$88.04MN/A673
ABVX
Abivax
3.6839 of 5 stars		$92.36
+2.6%		$155.00
+67.8%		-16.2%$8.09BN/AN/A98
ALKS
Alkermes
2.4429 of 5 stars		$47.49
+2.2%		$55.06
+15.9%		+41.6%$7.97B$1.48BN/A2,050

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:LKFT) was last updated on 11/12/2026 by MarketBeat.com Staff.
From Our Partners
Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...
Base Camp Trading | Sponsoredtc pixel
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...
Behind the Markets | Sponsoredtc pixel
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...
Weiss Ratings | Sponsoredtc pixel
URGENT: If you own a home, please review the map below.
More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...
Paradigm Press | Sponsoredtc pixel
Many investors are about to lose everything
Twenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...
Porter & Company | Sponsoredtc pixel
Management just bought 2.8 million shares
Management just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...
Monument Traders Alliance | Sponsoredtc pixel
Elon wants to move AI off the planet. Amazon isn't ready.
What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...
StocksToTrade | Sponsoredtc pixel